iFLYTEK's subsidiary, iFLYTEK Healthcare Technology, was officially listed on the Hong Kong Stock Exchange, becoming a pioneer company in the field of large medical models in China. In less than half a year since its listing, Tao Xiaodong, president of iFLYTEK Healthcare Technology, revealed in an interview with the media that, based on market demand and future predictions, the company expects to achieve profitability within 1 to 2 years.
According to the company's latest financial report, iFLYTEK Healthcare Technology achieved a revenue of 734 million yuan in 2024, an increase of 32% compared to the previous year. Although it still recorded a loss of 133 million yuan, the loss amount decreased compared to the previous year. Notably, iFLYTEK currently holds 49.42% of the shares in the company. The revenue from the intelligent healthcare business reached 692 million yuan, accounting for 2.96% of its total revenue. This indicates that iFLYTEK Healthcare Technology is in a stage of rapid development, and its future potential is significant.
Currently, iFLYTEK Healthcare Technology is one of the few listed companies that take artificial intelligence as its core business and provide services across all aspects of the medical system. Its product line covers three terminals: government, doctors, and patients, including smart assistants, intelligent hospital solutions, and smart medical devices. Tao Xiaodong pointed out that the commercial value of AI in the medical field still needs further verification, but he remains optimistic about future market opportunities, especially in auxiliary diagnosis and health consultation services.
To enhance market competitiveness, iFLYTEK Healthcare Technology launched the Starfire Medical Large Model V2.5 International Edition on June 24th, upgrading the iFLYTEK Xiao Yi APP. The new version not only expanded coverage of common diseases and medicines, but also ranked first with a score of 98.4 in comprehensive capability evaluation. This move undoubtedly lays a solid foundation for its further expansion in the medical AI market.
However, Tao Xiaodong also pointed out that medical large models are still under continuous development and have not yet fully taken off. He stated that AI in the medical field faces challenges, including how to understand local culture and regulations. Moreover, the ability of large models to communicate with patients still needs improvement, which is one of the key areas for future development.
The prospects of iFLYTEK Healthcare Technology in the field of medical AI are worth looking forward to. It is expected to achieve profitability through continuous innovation and market expansion in the future.